Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Current Assets (2016 - 2025)

Cardiff Oncology (CRDF) has disclosed Current Assets for 15 consecutive years, with $60.1 million as the latest value for Q4 2025.

  • Quarterly Current Assets fell 36.74% to $60.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $60.1 million through Dec 2025, down 36.74% year-over-year, with the annual reading at $60.1 million for FY2025, 36.74% down from the prior year.
  • Current Assets hit $60.1 million in Q4 2025 for Cardiff Oncology, down from $61.8 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $146.1 million in Q4 2021 to a low of $59.3 million in Q3 2024.
  • Historically, Current Assets has averaged $98.5 million across 5 years, with a median of $93.9 million in 2023.
  • Biggest five-year swings in Current Assets: skyrocketed 1150.33% in 2021 and later crashed 36.74% in 2025.
  • Year by year, Current Assets stood at $146.1 million in 2021, then dropped by 23.84% to $111.3 million in 2022, then tumbled by 30.44% to $77.4 million in 2023, then grew by 22.79% to $95.1 million in 2024, then plummeted by 36.74% to $60.1 million in 2025.
  • Business Quant data shows Current Assets for CRDF at $60.1 million in Q4 2025, $61.8 million in Q3 2025, and $73.7 million in Q2 2025.